Ads
related to: new drug for prostate cancer- Need a Second Opinion?
Put Our Expertise to Work for You.
Get a Virtual Second Opinion Today.
- Prostate Cancer
Discover Prostate Cancer Treatments
Download our Prostate Cancer Guide
- Virtual Second Opinions
Get Peace of Mind from Home.
Review Your Diagnosis & Treatment.
- Prostate Cancer Treatment
Download our Prostate Cancer Guide
Find Prostate Cancer Treatments
- Need a Second Opinion?
Search results
Results from the WOW.Com Content Network
The new drug "shows promise in treating advanced or aggressive prostate cancer," a doctor told Fox News Digital. "We know that CDK 9 is an enzyme associated with prostate cancer growth," he told ...
Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. [2] [9] It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), [2] nonmetastatic castration-resistant prostate cancer, [2] and metastatic castration-sensitive prostate ...
STAMPEDE (clinical trial) Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) is a clinical trial investigating treatments for high risk or terminal prostate cancer. Recruitment started in 2005 and ended in 2022; as of January 2020, over 10,000 participants had joined the trial.
Abiraterone acetate, sold under the brand name Zytiga among others, is a medication used to treat prostate cancer. [ 9 ] Specifically it is used together with a corticosteroid for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC). [ 2 ][ 3 ] It should either be used ...
A total of 150 people took part in the trial. Patients with advanced prostate cancer have a greater chance of survival if treated with a targeted cancer drug in addition to chemotherapy, according ...
Apalutamide was approved by the Food and Drug Administration in the United States, under the brand name Erleada, for the treatment of non-metastatic castration-resistant prostate cancer in February 2018. [8] [9] It was subsequently approved in Canada, the European Union, and Australia. [42] [6]
Ads
related to: new drug for prostate cancer